Novartis CEO in the hotseat after revelation that his company submitted falsified data to the FDA - The Boston Globe
Novartis Has Dropped Some Cancer Drugs From Pipeline, CEO Says | Barron's
Novartis - Today we announced appointment of Vasant (Vas) Narasimhan, M.D., Global Head of Drug Development and Chief Medical Officer, as the new CEO of Novartis, effective February 1, 2018. We thank
Novartis chief's 2018 take-home pay suffers—not from Cohen but from low-grade returns | Fierce Pharma
Novartis boss warns US drug pricing reform poses risk to public health | Financial Times
Vas Narasimhan talks to Monocle - Novartis Live. Magazine
How Novartis's CEO Learned From His Mistakes and Got Help From an Unlikely Quarter - WSJ
Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft | Reuters
Vasant Narasimhan | Novartis
Novartis CEO: Leqvio, Pluvicto off to good U.S. launch
How to get ordinary people to do extraordinary things: Novartis CEO Vas Narasimhan on the multiplier
Novartis's Vas Narasimhan on AI, Data Science for Company Operations
novartis: Who is Vas Narasimhan? All about the new global chief executive of Swiss pharma giant Novartis - The Economic Times
Novartis CEO Vas Narasimhan: Our medicines are starting to take market share and deliver on promises - YouTube
Novartis CEO Vas Narasimhan: How to be a boss in an “unbossed” company - YouTube
Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and more - STAT
Vas Narasimhan | One Young World
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis appointed Vasant Narasimhan as CEO, effective February 1, 2018
Novartis CEO Vas Narasimhan visits Slovenia - Lek
Novartis launches strategic review of generics business Sandoz | Financial Times
Novartis CEO Battles Fallout From Data Manipulation - WSJ
Vas Narasimhan auf LinkedIn: As Novartis marks our Annual Results today, there are many achievements to… | 37 Kommentare
